Altoida Celebrates Historic Day for Patients with Alzheimer’s Disease

Altoida Celebrates Historic Day for Patients with Alzheimer’s Disease

October 19, 2022Neelem Sheikh

Today marks a historic day for all the scientists and researchers who have dedicated their lives to advancing our understanding of Alzheimer’s Disease over the last 20 years. For the more than 6 million individuals living with Alzheimer’s disease in the US, their families, and their caretakers, our team at Altoida celebrates the positive topline data reported on the CLARITY AD global Phase 3 clinical trial of Eisai and Biogen’s Lecanemab. 

The theme of World Alzheimer’s Awareness Month, which is every September, is the power of knowledge. Many people think that Alzheimer’s disease is a normal part of aging, it isn’t. It is a progressive neurodegenerative disease that we believe can be slowed, stopped, and hopefully, prevented.

Lecanemab is an investigational therapy which acts as a disease-modifying agent and showed positive results in a large Phase 3 clinical trial. These results come after aducanumab became the first amyloid-clearing drug to win FDA approval. In this study on lecanemab, the rate of cognitive decline decreased by 27% for patients on therapy in a clinical trial as well as amyloid plaques. 

As more disease-modifying agents come to market, innovation is needed to enable earlier detection and diagnosis of Alzheimer’s Disease and effective management of patients receiving therapy.

At Altoida, our team is developing the leading AI-driven digital diagnostics and management platform to accelerate and improve drug development, research, and care for patients with neurological diseases. Our innovative approach leverages immersive augmented reality (AR) and proprietary algorithms to evaluate the brain in a comprehensive, real-world mode of functioning and identify subtle cognitive changes. Our validated and evidence-based platform received FDA Breakthrough Device Designation in July 2021. We are continuing to advance Alzheimer’s research in collaboration with Eisai and Ionian University to gain new insights into the Alzheimer’s Disease continuum from various aspects of observational data. 

Altoida is committed to advancing research and innovation for the early detection of Alzheimer’s Disease. We believe in health equity, access, and taking a precision approach to Alzheimer’s Disease that's driven by technology. The increasing integration of digital tools in healthcare will improve diagnosis, treatment, and management for everyone suffering from this debilitating neurological disease. 

As we celebrate the success announced today, we must continue our efforts to discover new innovation and research to accelerate drug development in Alzheimer’s and all other dementias. 

https://eisai.mediaroom.com/2022-09-27-LECANEMAB-CONFIRMATORY-PHASE-3-CLARITY-AD-STUDY-MET-PRIMARY-ENDPOINT,-SHOWING-HIGHLY-STATISTICALLY-SIGNIFICANT-REDUCTION-OF-CLINICAL-DECLINE-IN-LARGE-GLOBAL-CLINICAL-STUDY-OF-1,795-PARTICIPANTS-WITH-EARLY-ALZHEIMERS-DISEASE

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 

CONTACT@ALTOIDA.COM

Follow Us

Policy

By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.


Our Disclaimer

@ Altoida 2022